Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

NCT06500273 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Large B-cell Lymphoma

Interventions

GENETIC: cemacabtagene ansegedleucel
DRUG: Fludarabine
DRUG: Cyclophosphamide
DEVICE: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

Sponsor

Allogene Therapeutics

Collaborators

[object Object]